PMFBP1

Across TCGA pan-cancer cohorts, PMFBP1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PMFBP1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PMFBP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PMFBP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, CHOL, and KIRC are the cancer types where PMFBP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.124	0.703	<.001	30	view →
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
KIRC	OS	Median	All	0.181	0.805	.002	21	view →
DLBC	DFS	Median	II,III,IV	0.097	0.834	<.001	12	view →
PAAD	OS	Median	II,III,IV	0.205	0.556	.002	12	view →
BRCA	OS	Median	III,IV	0.500	0.906	.021	10	view →
LUSC	OS	Median	II,III,IV	0.166	0.426	.012	10	view →
UCEC	DFS	Median	All	0.972	0.828	.019	8	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →
SKCM	OS	Median	All	0.710	0.790	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PMFBP1–ESCA (OS)

Open the ESCA breakdown →